// App-Quantinova.ai

4643 : Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in France Interim Results From a Large Observational Study

Researchers

Presenter

  • Philippe Quittet

Principal Investigators

  • Mohamed Hamidou

  • Bernard Bonnotte

  • Olivier Fain

  • Kerry Dillingham

  • Georg Kreuzbauer

Medical Centers

  • Medecine Interne, Hopital Jean-Verdier, AP-HP, universite Paris-, BONDY Cedex, France

  • Service Medecine Interne, CHU Hopital du Bocage, Dijon, France

  • Dermatology, CHU Montpellier, Montpellier, France

  • Service de Medecine Interne,

Locations

  • France

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Immune thrombocytopenia

  • Deep vein thrombosis

  • Pulmonary embolism

  • Thrombocytopenia

  • Myelofibrosis

  • Venous thrombosis

Biomarkers

  • Aldo-Keto Reductase Family 1 Member B

  • Cluster of differentiation 95

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Romiplostim

  • Rituximab

Outcome

  • N/A

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved